绿叶制药集团与阿斯利康就英国、中国以及其他国际市场中思瑞康及思瑞康缓释片的权利签署价值5.46亿美元的协议

2018年5月7日，金杜跨境业务团队协助绿叶制药集团有限公司（“绿叶制药”）与阿斯利康签署交易，交易涉及思瑞康及思瑞康缓释片在英国、中国和49个其他国际市场，包括巴西、澳大利亚、沙特阿拉伯、墨西哥、韩国、泰国、阿根廷、马来西亚和南非中的资产出售和权利许可。转让资产及许可资产的收购总价为5.46亿美元，并将分为四期支付。

On 7th May, 2018, King & Wood Mallesons’ cross-border team, advised Luye Pharma Hong Kong Limited (“Luye Pharma”) on its transaction signed with AstraZeneca relating to the sale and licence of the rights to Seroquel and Seroquel XR in the UK, China and other 49 international markets, including Brazil, Australia, Saudi Arabia, Mexico, South Korea, Thailand, Argentina, Malaysia and South Africa. The purchase price for the transferred and licensed assets is US$546 million and is payable in four instalments.

若交割条件可得满足，本次交易预计将在2018年第二季度完成。作为交易的一部分，绿叶集团将于交易正式完成时或之前，与阿斯利康签订供应协议，以从阿斯利康处获供应已制成的产品。根据阿斯利康提供的资料，截至2017年12月31日止，关联产品于相关地区的销售额，约为1.479亿美元。

The transaction is expected to close by the end of Q2 2018, subject to customary closing conditions. As part of the transaction, Luye Pharma group will enter into a supply agreement with AstraZeneca for the supply of finished products from AstraZeneca at or prior to the formal closing of the transaction. According to information provided by AstraZeneca, sales of the products in the relevant territories for the year ended 31 December 2017 amounted to approximately US$147.9 million.

绿叶制药专注于开发、生产、推广及销售四个规模最大及增长速度最快的治疗领域（即肿瘤、心血管、新陈代谢和中枢神经系统）的创新产品，产品覆盖全球主要制药市场。阿斯利康是一家科学至上的全球性生物制药企业，专注于处方药的研发和商业化，业务重点主要集中于三大治疗领域——肿瘤、心血管及代谢疾病和呼吸。该项目涉及的思瑞康（富马酸喹硫平，速释片，IR）和思瑞康缓释片（缓释制剂）是一种具有抗抑郁特性的非典型抗精神病药物。在若干市场上，思瑞康也被批准用于抑郁症和广泛性焦虑症。绿叶制药相信，对思瑞康及思瑞康缓释片的收购，将有助于绿叶制药在国内的进一步发展，并进入海外市场。

Luye Pharma focuses on developing, producing, marketing and selling innovative pharmaceutical products in four of the largest and fastest growing therapeutic areas — oncology, cardiovascular, metabolism and the central nervous system, covering the main global pharmaceutical markets.  AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. Seroquel (quetiapine fumarate, immediate release, IR) and Seroquel XR (extended release formulation) are atypical anti-psychotic medicines with antidepressant properties. The main indications for Seroquel are the treatment of schizophrenia and bipolar disorder. Seroquel XR is also approved in some markets for major depressive disorder and generalised anxiety disorder. Luye Pharma believes that the acquisition of Seroquel and Seroquel XR will assist further expansion in the PRC and into markets outside of China.

本次金杜跨境业务团队的负责合伙人是北京办公室的黄建雯（公司及并购），团队成员其他核心成员还包括合伙人宁宣凤（反垄断）、陈文平（知识产权）、楼仙英（知识产权）和章慈（税务）。伦敦办公室的负责合伙人为Greg Stonefield（公司法）和Barri Mendelsohn（公司法），伦敦其他参与项目的成员还包括合伙人Joseph Newitt (公司法)，顾问Anna Feros (知识产权)， Sam Coleman (税务)， 以及合伙人David Wilman (劳动法) 。 

KWM’s cross border-team was led by Beijing based partner Jianwen Huang (Corporate & MA) , and partners Susan Ning (Anti-trust), Wenping Chen (IP), Xianying Lou (IP) and Ci Zhang (Tax) were key team members. The London team was led byGreg Stonefield (Corporate) and Barri Mendelsohn (Corporate) with other London team members comprising Joseph Newitt (Corporate), Anna Feros (IP ), Sam Coleman (Tax), and David Wilman (Employment). 

黄建雯律师评论道：“我们十分荣幸能有此机会参与到绿叶制药这一里程碑式的战略性交易中，也相信本次交易将有助于绿叶制药在全球市场中的发展。本次交易是一个绝佳案例——不仅展示了金杜应对复杂跨境交易的综合管理方式，更体现了我们国际资源的深度和实力，以协助客户取得成功。 

Jianwen Huang commented that “We are honoured to have had the opportunity of participating in this landmark strategic transaction for Luye Pharma which we believe will contribute to Luye Pharma’s  global development.  This transaction is a superb example that demonstrates not only our integrated approach to complex cross border transactions but also the depth and strength of our international resources to achieve a successful outcome for our clients.”

Greg Stonefield表示：“ 我们的客户正寻求拓展其在世界各地的业务，我们很高兴能与中国办公室团队一起为中国客户就此项重大交易提供支持。我们非常擅长为中国客户的国际交易及国际客户向中国的投资提供法律服务。我们期待在今后能为绿叶和其他公司继续提供更多帮助。”

Greg Stonefield said, “We are delighted to support our China team and a key client of the firm on this important transaction, as our client seeks to expand its business offering and presence around the world.  We are ideally suited to advise China-based clients on their international transactions and international clients seeking to invest in China and we look forward to continuing to support Luye and others as this trend continues.”

金杜欧洲及中东地区管理合伙人王荣康律师表示：“本次交易是我们的全球团队为我们中国客户的关键战略交易和计划提供高效服务的又一实例。” 

Rongkang Wang, Managing Partner of KWM EUME, said “This is yet another example of our global team working together effectively to deliver results for our Chinese clients on key strategic transactions and initiatives.”

绿叶法务团队评论道：“黄律师和金杜团队在整个交易中的重要性是不可替代的。为金杜律师的超高专业水平点赞。” 

Luye Legal Team commented, “Ms. Huang and the King & Wood Mallesons legal team were irreplaceable in the whole transaction. We highly appreciate the professional assistance from King & Wood Mallesons’ legal team.”